Stem cells in normal tissues and cancer-initiating cells (CICs) are known to be enriched in side population (SP) cells. However, the factors responsible for the regulation of expression of ABCG2, involved in efflux of dyes, in SP cells have not been fully investigated. Here, we characterized the SP cells within diffuse-type gastric carcinoma, and examined the effects of transforming growth factor-b (TGF-b) on SP cells. Diffuse-type gastric carcinoma cells established from four independent patients universally contained SP cells between 1 and 4% of total cells, which displayed greater tumorigenicity than non-SP cells did. TGF-b repressed the transcription of ABCG2 through direct binding of Smad2/3 to its promoter/enhancer, and the number of SP cells and the tumor-forming ability of cancer cells were decreased by TGF-b, although ABCG2 is not directly involved in the tumor-forming ability of SP cells. Cancer cells from metastatic site expressed much higher levels of ABCG2 and included a greater percentage of SP cells than parental cancer cells did. SP cells are thus responsible for the progression of diffuse-type gastric carcinoma, and TGF-b negatively contributes to maintain the CICs within the cancer.
Introduction
Gastric cancer remains a major public health issue as the fourth most common cancer and the second leading cause of cancer death worldwide (Hohenberger and Gretschel, 2003; Crew and Neugut, 2006) . Of the two histological subtypes of gastric cancers, the incidence of proximal, diffuse-type gastric adenocarcinoma has been increasing, particularly in Western countries. Diffusetype gastric carcinoma is an aggressive type of gastric cancer with poor prognosis, affecting relatively young individuals. The majority of diffuse-type gastric carcinomas are in advanced stages, for which gastrectomy and chemotherapy are of limited efficacy. Thus, understanding of the mechanism underlying progression of diffuse-type gastric carcinoma is essential for management of this tumor.
The concept of 'cancer stem cells' or 'cancer-initiating cells (CICs)' is an attractive explanation for the functional heterogeneity that is commonly observed in many types of tumors. Tumors possess a hierarchical organization of cells, among which a subpopulation of stem-like cells is responsible for sustaining tumor growth (Stingl and Caldas, 2007; Visvader and Lindeman, 2008) . As these cells are likely to share many of the properties of normal stem cells, which have a long lifespan, self-renewal ability, resistance to drugs, active DNA-repair activity and resistance to apoptosis, the presence of CICs is thought to be important for progression of tumors and resistance to conventional therapies (Dean et al., 2005) . Recently, CICs have been identified in a range of hematopoietic malignancies and solid tumors (Bonnet and Dick, 1997; Lobo et al., 2007) . In the maintenance of CICs, the interaction of CICs and 'niche' has critical roles, and factors secreted from the tumor microenvironment appear to regulate the maintenance of CICs in certain niches (Iwasaki and Suda, 2009 ). However, the factors responsible for regulation of the CIC pool have not been fully investigated.
Transforming growth factor-b (TGF-b) is the prototypic member of a family of secreted proteins that includes three isoforms of TGF-b (TGF-b1, TGF-b2 and TGF-b3), activins and bone morphogenetic proteins (BMPs). TGF-b mediates biological activities in cells through binding to heteromeric complexes of receptors on the cell surface that are composed of TGF-b type I and type II (TbRII) receptors. TGF-b type I receptor activated by TbRII phosphorylates Smad2 and Smad3, which interact with Smad4 and translocate to the nucleus. Nuclear Smad2/3-Smad4 complexes bind to transcription factors and transcriptional co-activators/ repressors, and regulate transcription of target genes (Miyazawa et al., 2002; Derynck and Zhang, 2003; Massague´, 2008) . In epithelial cells, TGF-b inhibits cell proliferation, induces apoptosis and mediates differentiation, suggesting that components of the TGF-b signaling pathways have tumor-suppressive activity in epithelial tumors (Wakefield and Roberts, 2002; Bierie and Moses, 2006) . Accordingly, mutations of TbRII, TGF-b type I receptor, Smad4 and Smad2, have been reported to be responsible for progression of cancers, particularly gastrointestinal tumors (Bierie and Moses, 2006) .
We previously reported that deregulation of the TGFb signaling pathway in the diffuse-type gastric carcinoma OCUM-2MLN cells, which were derived from lymph node metastasis of orthotopically implanted primary carcinoma cells, promotes the growth of primary tumors in mouse xenograft models through acceleration of angiogenesis (Kiyono et al., 2009; Komuro et al., 2009) . In addition to this mechanism, we here present evidence that TGF-b has a novel role in regulation of the maintenance of CICs in diffuse-type gastric carcinoma cells. Our observations provide new insights into the molecular mechanisms governing TGFb-mediated regulation of gastric carcinogenesis and may support the development of new strategies for the treatment of diffuse-type gastric carcinoma.
Results

CICs are enriched in 2MLN-dnTbRII cells
Tumor growth of diffuse-type gastric carcinoma OCUM-2MLN cells is reported to be enhanced by inhibition of the TGF-b signaling pathway in cancer cells (Kiyono et al., 2009; Komuro et al., 2009) . In accordance with these reports, TGF-b-induced phosphorylation of Smad2 was completely inhibited in OCUM-2MLN cells, which stably expressed dominant negative form of TbRII (2MLN-dnTbRII), but not in control cells, which expressed green fluorescent protein (2MLN-GFP) (Figure 1a ). TGF-b inhibited the proliferation of keratinocyte HaCaT cells in vitro, whereas TGF-b did not affect the rate of growth of the OCUM-2MLN cells (Figure 1b) . Cells enter the S phase and proliferate when the phosphorylated retinoblastoma protein (RB) is hyperphosphorylated, whereas cells are arrested in G1 when phosphorylated RB is hypophosphorylated (Weinberg, 1995) . Treatment of HaCaT cells with TGF-b decreased hyperphosphorylated RB expression, whereas hyperphosphorylated RB expression in OCUM-2MLN cells was not altered by TGF-b (Figure 1c) . In contrast to in vitro cell proliferation, in vivo tumor growth of 2MLN-dnTbRII cells was accelerated in the subcutaneous mouse tumor model compared with that of 2MLN-GFP cells (Figure 1d ). In the previous study, we showed that angiogenesis was accelerated in 2MLN-dnTbRII tumors through repression of the expression of the anti-angiogenic factor thrombospondin-1 . However, thrombospondin-1 expression is not sufficient to account for all the histological change in tumor obtained by the overexpression of dnTbRII, such as the accumulation of fibrotic tissues. Thus, we attempted here to uncover additional underlying mechanisms by which the deregulation of TGF-b signaling in OCUM-2MLN cells promotes in vivo tumor growth, and especially focused on the heterogeneity of cancer cells.
We examined whether 2MLN-dnTbRII cells include a higher proportion of CICs than 2MLN-GFP cells do. Various amounts of 2MLN-GFP and 2MLN-dnTbRII cells were injected into nude mice and compared for tumor-forming ability (Figure 1e ). In 2MLN-dnTbRII cells, subcutaneous tumor formation required injection of 1 Â 10 3 cells, whereas injection of 3 Â 10 3 2MLN-GFP cells constantly failed to induce tumor formation in all mice examined (n ¼ 4). These findings suggested that 2MLN-dnTbRII cells promote tumor formation through enrichment of CICs in cancer cells.
ABCG2 is highly expressed in 2MLN-dnTbRII tumors
We hypothesized that TGF-b from the tumor microenvironment decreases the tumor-forming ability of OCUM-2MLN cells in vivo. To examine the alterations caused by disruption of the TGF-b signaling pathway in diffuse-type gastric carcinoma cells in vivo, we made use of comprehensive gene expression data sets for these tumors previously obtained using oligonucleotide microarray analysis ). In our previous study, DAVID functional annotation clustering revealed that the expression of thrombospondin-1 in tumor tissues was increased by TGF-b, and thrombospondin-1 was reported as one of the 'TGF-b-positively regulated genes' in OCUM-2MLN cells (Dennis et al., 2003) . However, novel candidate gene(s) related to the 'tumor-forming ability' or 'stemness' of 2MLN-dnTbRII cells was not picked up among these 'TGFb-positively regulated genes'. Thus, genes that were strongly expressed in 2MLN-dnTbRII tumors, namely 'TGF-b-negatively regulated genes', were focused, and identified as shown in Figure 2a .
Among the 30 genes upregulated in 2MLN-dnTbRII tumors, ATP-binding cassette G2 (ABCG2) was included ( Figure 2a ). ABCG2 contributes to efflux of many types of dyes, including Hoechst 33342. Although uptake of Hoechst 33342 occurs universally in all cells, efflux of it is less common. Cells with efflux capacity conferred by ABCG2 expression are negatively stained on flow cytometric analysis, and referred to as side population (SP) cells on dot plots. As ABCG2 expression and SP cells are thought to be of importance in the isolation of CICs (Wu and Alman, 2008) , we focused on the function of ABCG2. In order to confirm the involvement of the Smaddependent signal transduction by TGF-b, we knocked (Figure 3a) . Furthermore, the decrease in expression of ABCG2 by TGF-b was not abolished by suppression of de novo protein synthesis by treatment of OCUM-2MLN cells with cycloheximide ( Figure 3d ). To determine whether ABCG2 is a direct target of TGFb in OCUM-2MLN cells, we performed chromatin immunoprecipitation using antibody against Smad2/3, DNA-binding mediators of Smad-dependent signal transduction. We have demonstrated that activated Smad2/3 directly bound to the promoter elements located in 200 bp upstream of the start point of transcription of ABCG2 and also bound to the enhancer element located in the first intron of ABCG2 in response (Figure 6a ). TGF-b-mediated regulation of SP cells was also observed in other diffuse-type gastric carcinoma cells (Figure 6b ). These results were correlated to the expression of ABCG2 (Figures 3a and 4a) .
Next, we examined whether TGF-b decreases the tumor-forming potential of OCUM-2MLN cells in vitro and in vivo. Colony formation of OCUM-2MLN cells was inhibited by treatment with TGF-b (Figure 6c) . In a mouse xenograft experiment, subcutaneous tumor was formed by the injection of 1 Â 10 5 control cells, while TGF-b-treated cells exhibited limited tumorigenesity even if the same amounts of control cells were injected (Figure 6d ). These findings suggested that TGF-b decreased the SP fraction of OCUM-2MLN cells, and thereby attenuated the tumor-forming ability of OCUM-2MLN cells.
Silencing of endogenous ABCG2 does not affect the tumorigenesis of OCUM-2MLN cells Next we examined whether the ABCG2 expression is functionally linked to the tumorigenic activity of OCUM-2MLN cells. We established the cells termed 2MLN-shRNA/ABCG2, whose expression of ABCG2 was stably knocked down by the transfer of short hairpin RNA (Supplementary Figure S1A) . Though successful silencing of endogenous ABCG2 expression was achieved, 2MLN-shRNA/ABCG2 cells exhibited a Figure  S1B) . (Figure 7a ). Flow cytometric analysis revealed that OCUM-2M, OCUM-2MLN, OCUM-2MD3 and OCUM-2D cells included SP cells at 0.00, 1.54, 0.14, and 0.04% of total cell populations, respectively (Figure 7b ). Consistent with these findings, expression of ABCG2 in OCUM-2MLN cells was significantly higher than that in the other types of gastric carcinoma cells, and that TGF-b suppressed the expression of ABCG2 messenger RNA (Figure 7c ). In a mouse xenograft experiment, only OCUM-2MLN cells, and 
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Discussion
CICs are enriched in SP cells in diffuse-type gastric carcinoma The existence of CICs within human gastric carcinoma was first detected by in vitro colony formation assay in 1981 (Laboisse et al., 1981) . Recently, a number of markers have proved useful for isolation of the subsets enriched in CICs in multiple cancers (Visvader and Lindeman, 2008) . Some gastric cancer cells include subpopulations of CD44 þ cells, which exhibited tumorigenic ability (Takaishi et al., 2009 ). However, no specific 
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marker for the diffuse-type gastric carcinoma-initiating cells has yet been established. In this study, we provide evidence that CICs are present in diffuse-type gastric carcinoma cells, and that the SP cells in OCUM-2MLN cells possessed repopulating capacity and high tumorforming ability in vivo.
SP cells were initially identified in mouse bone marrow as long-term repopulating cells (Goodell et al., 1997) . This original discovery was followed by other reports on a wide variety of tissues (Zhou et al., 2001) . High expression of ABCG2 in hematopoietic stem cells was also reported (Scharenberg et al., 2002) . Moreover, recent studies have revealed that not only stem cells in normal tissues but also CICs are enriched in SP cells in many types of cancers (Wu and Alman, 2008) . Our findings suggest that CICs in diffuse-type gastric carcinoma are enriched in SP fraction, and that expression of ABCG2 might serve as a marker for diffuse-type gastric cancer-initiating cells. As SP cells are estimated to be present at proportions between 0 and 20% of total cell population in many types of cancers (Dean et al., 2005; Wu and Alman, 2008) , it is reasonable that diffuse-type gastric cancer cells include SP cells in the range of 0-4% to total cancer cells.
Population of CICs is decreased by TGF-b: a novel mechanism of tumor suppression TGF-b acts as tumor suppressors in many types of cancer. In gastrointestinal tumors, genetic and epigenetic inactivation of TGFBR2, TGFBR1, SMAD4/ MADH4 and SMAD2/MADH2 has been found (Hahn et al., 1996; Markowitz and Roberts, 1996; Grady and Markowitz, 2008) . Consistent with these findings, we have shown that overexpression of dnTbRII in OCUM-2MLN cells caused the accelerated tumor formation in vivo in a mouse xenograft model (Figure 1d ). However, under in vitro condition, phosphorylation of Smad2 in those cells was not detected in the absence of exogenous TGF-b, and detected only after the treatment of exogenous TGF-b (Figure 1a) . Thus, TGF-b may be supplied from tumor microenvironment, for example, cancer-associated fibroblasts (Mizoi et al., 1993) , and have an influence on tumorigenicity of cancer cells.
Interestingly, TGF-b altered the percentage of CICs within diffuse-type gastric carcinomas. As TGF-b suppressed the expression of ABCG2 in other types of cancer cells (Figure 4) , it is possible that the percentages of CICs in other types of cancers are also decreased by TGF-b. However, contrary to the present findings for diffuse-type gastric carcinomas, TGF-b was reported to maintain the 'stemness' of glioblastoma-initiating cells (Ikushima et al., 2009; Pen˜uelas et al., 2009) . TGF-b also maintains the stem-cell-like properties of leukemiainitiating cells in chronic myeloid leukemia through regulation of AKT activation and FOXO3a localization (Naka et al., 2010) . TGF-b might thus have different, tissue-dependent regulatory effects on CICs.
We also examined the effect of BMP-4, another member of TGF-b family, on the expression of ABCG2 and the maintenance of SP cells within diffuse-type gastric carcinoma. In several types of cancers, BMP ligands are estimated as a novel therapeutic agent, which can induce 'differentiation' of cancer stem cells, attenuate the tumor-forming ability of cancer, and may be used to prevent growth and recurrence of cancers (Piccirillo et al., 2006; Sneddon et al., 2006; Lee et al., 2008) . However, BMP-4 reduced neither the expression of ABCG2 in OCUM-2MLN cells nor population of SP cells in these cells (Figure 3a, b and 6a) .
TGF-b regulates the expression of ABCG2 and drug efflux ability ABCG2, also termed BCRP, is a 72 kDa half-transporter containing six putative transmembrane a-helices (Velamakanni et al., 2007; Gradhand and Kim, 2008) , and is a member of subfamily G of the ABC transporters, expressed in various types of cancers. ABCG2 is known to be responsible for the efflux of chemotherapeutic drugs. Thus, pharmacological inhibition of ABCG2 activity with selective inhibitors was tested in an attempt to overcome ABCG2-mediated drug resistance. In addition, siRNA targeting ABCG2 expression in cancer cells was also designed. However, the mechanism of regulation of ABCG2 expression in cancer cells have yet to be fully understood. Here, we found that ABCG2 expression was repressed by TGF-b in several types of cancers, including diffuse-type gastric carcinoma. These findings are in agreement with the observations using human breast cancer MCF7 cells (Yin et al., 2008) . TGF-b appears to directly regulate the expression of ABCG2 in diffuse-type gastric carcinoma cells. Moreover, we have demonstrated that Smad complex directly binds to ABCG2 promoter/enhancer in OCUM-2MLN cells and that TGF-b negatively regulates the transcription of ABCG2 in these cells (Figure 3e ). This is consistent with our recent chromatin immunoprecipitation-chip analysis data, which indicated that Smad2/3 complex directly binds to the transcription start point of the ABCG2 locus in the genome of human normal keratinocyte, HaCaT cells (Koinuma et al., 2009 and our unpublished data) .
Metastasis of diffuse-type gastric carcinoma might depend on a distinct population of tumor cells Recent findings have suggested that in some cancers metastasis arises directly from CICs. Pancreatic cancer stem cells, profiled as CD133 þ CXCR4 þ , exhibited significantly stronger migratory activity in vitro (Hermann et al., 2007) . Furthermore, CD44
þ CD24 À/low cells, a cancer-initiating subset of breast cancer, are readily detectable in pleural effusions in breast cancer patients (Al-Hajj et al., 2003) . Moreover, peritoneal metastasis of diffuse-type gastric carcinoma depends on the adhesive ability of cancer cells, and the adhesive ability of SP cells was reported to be significantly higher than that of parental cells ). This study demonstrated that OCUM-2MLN and OCUM-2MD3 cells, both of which were isolated from metastasis arising in OCUM-2M cell-xenografted mice, expressed higher levels of ABCG2 and included more SP cells than parental OCUM-2M cells. When equal numbers of OCUM-2M or OCUM-2MLN cells were orthotopically injected, lymph node metastases were only observed in the OCUM-2MLN-injected mice (Fujihara et al., 1998) . Intraperitoneal inoculation of OCUM-2MD3 cells caused peritoneal metastases in all treated mice, whereas that of OCUM-2M cells failed to induce peritoneal metastasis (Yashiro et al., 1996) . Taken together, these findings suggest that OCUM-2MLN and OCUM-2MD3 cells, which may include relatively large SP populations, have stronger metastatic ability than OCUM-2M cells. Metastasis of diffuse-type gastric carcinoma might be derived from a minority of tumor cells, and complete eradication of this minor population may be necessary for the effective treatment of cancer. Alternatively, induction of differentiation of the CICs by activation of TGF-b signaling pathway may be another possibility for eradication of this minor population.
Diffuse-type gastric carcinoma is characterized by its thick stromal fibrosis, thus, also known as linitis plastica. Although TGF-b produced by cancer cells and/or by cancer-associated fibroblasts enhances the fibrosis, the role of TGF-b in the development of diffuse-type gastric carcinoma still remains controversial (Mizoi et al., 1993; Mishra et al., 2005) . Either increased or decreased survival in diffuse-type carcinoma patients were reported to correlate with the expression of TGF-b (Kinugasa et al., 1998; Vagenas et al., 2007) . However, our present findings suggest that TGF-b suppresses the progression of tumor by induction of the differentiation of CICs of this type of cancer. Study of the interaction between CICs and the tumor microenvironment mediated through TGF-b signaling should provide additional insights into the management of cancer.
Materials and methods
Cell culture
Human diffuse-type gastric carcinoma cells were cultured as shown in Supplementary Table S1 (Takemura et al., 2004; Yashiro et al., 2009; Yanagihara et al., 1993) . Lentivirus vectors were used to generate 2MLN-dnTbRII and control 2MLN-GFP cells as described . A human keratinocyte cells, HaCaT, and a human breast cancer cells, MDA-MB-231, were cultured as described (Ehata et al., 2007a) . Human non-small-cell lung carcinoma cells, A549, human hepatocellular carcinoma cells, HuH7, and human cervical carcinoma cells, HeLa, were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, penicillin/streptomycin. siRNA siRNA duplex oligoribonucleotides against human Smad4 (Stealth RNAi VHS41118) or control siRNA (Stealth RNAi 12935-200) were synthesized by Invitrogen (Carlsbad, CA, USA). OCUM-2MLN cells were transfected in the presence of 125 pmol of either siRNA/Smad4 or control siRNA in a 500 ml volume with 8 ml Lipofectamine 2000 (Invitrogen) per well of a 6-well plate according to the manufacturer's protocols. To confirm knockdown of Smad4, cells were harvested 24 h after siRNA transfection and subjected to quantitative real-time RT-PCR.
RT-PCR
Quantitative real-time RT-PCR was performed as described (Ehata et al., 2007b) . Values were normalized to hypoxanthine guanine phosphoribosyl transferase 1 (HPRT1). All samples were run in duplicate. The primer sequences were listed in Supplementary Table S2 .
Immunoblotting Immunoblotting was performed as described (Ehata et al., 2007b; Komuro et al., 2009 ). Anti-phospho-phosphorylated RB antibody was obtained from BD Pharmingen (San Jose, CA, USA). Anti-ABCG2/BCRP antibody was obtained from Millipore (Billerica, MA, USA). LAS-4000 Image Analyzer (Fuji Photo Film, Kanagawa, Japan) was used for the detection of immunoblotted proteins.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as described (Koinuma et al., 2009 ). Whole-cell extracts were incubated at 4 1C for 8 h with Dynabeads sheep anti-mouse IgG (Invitrogen) that had been preincubated with 10 mg of anti-Smad2/3 antibody (Cell Signaling Technology, Beverly, MA, USA) in phosphate-buffered saline/0.5% bovine serum albumin. Genomic DNA was then extracted with a PCR Purification Kit (Qiagen, Valencia, CA, USA), eluted in l00 ml of Tris-EDTA, and used for quantitative real-time PCR. Hemoglobin beta (HBB) and plasminogen activator inhibitor type 1 (PAI-1) were used for negative and positive control, respectively. The primer sequences were listed in Supplementary Table S2 .
Cell proliferation assay Cell proliferation assay was performed as described (Ehata et al., 2007a) . Briefly, HaCaT and OCUM-2MLN cells were seeded in duplicate at a density of 2.5 Â 10 4 cells per well in 24-well plates. On the following day, cells were treated with TGF-b (1 ng/ml) for 4 days. Cells were trypsinized and counted with hemocytometer.
Colony formation assay in soft agar Agar (Nacalai Tesque, Kyoto, Japan) was dissolved in culture medium to 0.5% and plated in 6-well plates (bottom layer). Then, cells were seeded at 1-2 Â 10 4 cells per well in 0.3% agar (top layer) over bottom layer. Cells were covered with liquid growth media containing TGF-b, and cultured for 3 weeks. Cell viability was measured using Cell Count Reagent SF (Nacalai Tesque).
Flow cytometric analysis and sorting
Flow cytometric analysis and sorting were performed as described (Katayama et al., 2009) . Briefly, cells were resuspended at a concentration of 1 Â 10 6 cells per ml in ice-cold Hank's balanced salt solution supplemented with 2% fetal bovine serum and 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. These cells were treated with 1-12 mg/ml Hoechst33342 (Invitrogen) for 60 min at 37 1C either alone or in the presence of inhibitors. After washing with phosphate-buffered saline, 3 Â 10 4 cells were analyzed using a FACS Vantage SE flow cytometer (BD Biosciences, San Jose, CA, USA). Hoechst 33342 was excited with the UV laser at 350 nm and fluorescence emission was measured with 405/BP30 (Hoechst blue) and 570/BP20 (Hoechst red) optical filters. SP gate was defined as diminished region in the presence of reserpine or fumitremorgin C. Analysis was done using Flow Jo software (Treestar, Ashland, OR, USA).
Mouse xenograft model and in vivo gene expression analysis Animal experiments using a mouse xenograft model were performed . For the xenografts of sorted Reduction of SP cells in gastric cancer by TGF-b S Ehata et al cells, Matrigel (BD Bioscience) was used. The significance of differences was determined by repeated-measures analysis of variance test, with P-values less than 0.05 considered significant. In vivo gene expression analysis was performed as described . Briefly, tissue samples from subcutaneous 2MLN-GFP or 2MLN-dnTbRII tumors were digested with collagenase and trypsinized. The resulting single-cell suspension was subjected to magnetic cell sorting with magnetic microbeads conjugated to CD326 antibody (Miltenyi Biotec, Sunnyvale, CA, USA) to separate CD326-positive human cancer cells from CD326-negative mouse stromal cells. Total RNAs were purified with the RNeasy Mini Kit (QIAGEN) and used for oligonucleotide microarray, GeneChip Human Genome U133 Plus2.0 (Affymetrix, Inc. (Santa Clara, CA, USA)). MultiExperiment Viewer Version 4.6 software (Institute for Genomic Research) was used for the statistical analysis.
